Activating BRAF (V-raf murine sarcoma viral oncogene homolog B) mutations occur in approximately 5% to 10% of patients with metastatic colorectal cancer, mostly V600E mutation, and it is associated with distinct clinical and pathological features. To date, there are no approved treatments to target this mutation. BRAF inhibitor monotherapy has limited efficacy, in contrast to metastatic melanoma. Combination strategies that block not only BRAF mutated kinase but other alternative pathways are ongoing and have demonstrated improved activity. This review aims to provide data about new strategies to target to BRAF gene mutation in metastatic colorectal cancer.
Development of BRAF Inhibitor in Cancer Treatment
The prototype to treat BRAF V600E mutant cancer was metastatic melanoma, a tumor subtype with higher rates (50%) of BRAF V600E mutations. Sorafenib, a multikinase inhibitor, was the first drug studied with the ability to inhibit several targets including BRAF V600E mutation. Although this drug has activity against BRAF mutant metastatic melanoma in preclinical studies, it failed to demonstrate clinical efficacy in both single agent and combination with chemotherapy in phase II/III clinical studies. 12, 13 The data from phase I study with sorafenib at maximum tolerated dose showed no difference in the levels of phosphorylated MEK and ERK in pretreatment and posttreatment biopsies. 14 Vemurafenib and dabrafenib, more potent and selective BRAF V600E inhibitors, have been approved by the US Food and Drug Administration in 2011 and 2013; respectively, for treating BRAF mutated metastatic melanoma based on increases in both progression-free survival (PFS) and overall survival (OS) when compared with standard of care. 15, 16 The combination of dabrafenib and trametinib, targeting MEK, which is downstream of BRAF in the MAPK pathway, was also approved by the US Food and Drug Administration in 2014 based on increased PFS and OS over single dabrafenib or vemurafenib monotherapy. 17, 18 
BRAF Inhibitor Monotherapy in mCRC
Although vemurafenib, dabrafenib, and trametinib have been approved for treating BRAF mutated metastatic melanoma, disappointingly, these drugs had only scant activity when used as a monotherapy in mCRC.
Vemurafenib has selective affinity for the V600E mutant formation of BRAF, unlike sorafenib. Preclinical studies in BRAF mutant CRC cell lines showed the ability of vemurafenib to inhibit MAPK signaling pathway. 19 Kopetz et al. 20 reported a phase II study of vemurafenib in 21 mCRC patients with a response rate of only 5% (1 with partial response [PR] and 7 with stable disease [SD]). Median PFS and OS were 2.1 months (range, 0.4-11.6 months) and 7.7 months (range, 1.4-13.1 months), respectively. 20 A similar result was shown with dabrafenib. Among 9 patients, one had a confirmed PR, and 7 had SD. 21 Trametinib also showed no objective response in 28 mCRC patients, 22 although this was not limited to BRAF mutant tumors.
Combination Treatment
There are some data that suggested that a combined treatment with BRAF and MEK inhibitor can lead to decreases in MAPK signaling in BRAF mutant cell line. 23, 24 Based on this knowledge, Corcoran et al. 25 evaluated the combination of BRAF and MEK inhibitor with dabrafenib and trametinib in 43 patients. Four (9%) achieved PR, 1 (2%) had complete response with duration of response of more than 36 months, and 24 patients (56%) achieved SD. Median PFS was 3.5 months (95% confidence interval [CI], 3.4-4 months). Analysis of tumor biopsy confirmed that combination regimen decreased downstream activation of MAPK pathway but not to the degree seen with single-agent BRAF inhibition in melanoma. 25 From the *Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand; and †Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. S.K. was supported by ROI CA172670 + CA187238.
The mechanism for resistance to the monotherapy has been proposed to be through feedback activation of MAPK signaling pathway. Two groups independently reported a possible mechanism through EGFR activation. The first group reported that single-agent BRAF or MEK inhibitor cannot sustain the inhibition of the MAPK pathway in CRC cell lines. Negative feedback pathways can reactivate MAPK signaling through an increase in EGFR phospholylation, resulting in insensitivity to the drug. 26 Another group similarly demonstrated that vemurafenib increases activated EGFR activity, which reactivates the MAPK pathway. 27 In phase II study of vemurafenib in multiple nonmelanoma cancer with BRAF V600E mutations (VE-BASKET trial), there were 37 patients with mCRC. Twenty-seven of 37 patients were treated with vemurafenib plus cetuximab, and 10 of 37 patients were treated with single vemurafenib. The overall response rate in combination treatment was 4% (69% with SD) with median PFS and OS of 3.7 months (95% CI, 1.8-5.1 months) and 7.1 months (95% CI, 4.4 months to not reach), respectively. 28 Yaeger et al. 29 also reported the pilot study on vemurafenib and panitumumab in 12 BRAF mutant CRC patients, which showed a response rate of 13% with 53% of SD.
Overall, the data with combination of BRAF inhibitor and MEK or EGFR inhibitor suggest an improvement in efficacy over BRAF inhibitor monotherapy. However, some patients still do not response to these treatments, which may reflect that dual combination therapy may not be enough to suppress the signaling. Adding the third agent, which uses the EGFR + BRAF inhibitor backbone, can improve the response in this group. Atreya et al. 30 reported the data from 35 patients with BRAF mutant CRC who use triple combination of dabrafenib, panitumumab, and trametinib that showed response rate of 26% with additional 57% of SD, which was higher than the combination of 2 drugs.
Other Pathways
Other than the MAPK pathway, the activation of phosphatidylinositol 3-kinase (PI3K)/AKT pathway has also been implicated resistance to BRAF inhibitor both melanoma 31 and CRC cell line. 32 In mice xenografts model, treatment with vemurafenib and PI3K inhibitor showed higher rate of tumor growth inhibition when compared with vemurafenib alone. However, preliminary data from phase II study in combination of PI3K inhibitor with BRAF and EGFR inhibitor did not demonstrate a convincingly higher response rate than the BRAF and EGFR combination alone (overall response rate, 32% vs 23%, respectively) and no improvement in PFS. 33 Loss of function of APC gene leads to activation of canonical Wnt signaling pathway, which is one of the major causes of CRC tumorigenesis. In a minority of patients, Wnt signaling is activated by alternative mutations besides APC. One example of this is RNF43, which encodes an E3 ubiquitin ligase that negatively controls Wnt signaling. 34 Analysis of The Cancer Genome Atlas CRC data set reveals a co-occurrence of BRAFV6000E mutation and RNF43 mutation. Data from translation and preclinical studies suggest that Wnt pathway signals together with EGFR-MAPK pathway may promote tumor growth in BRAF V600E CRC. 35 A clinical trial with a small molecule porcupine inhibitor, a Wnt inhibitor, combined with BRAF and EGFR inhibition is ongoing.
Other than proliferation pathway, suppression of apoptotic signaling contributes substantially to tumor progression. Overexpression of the prosurvival B-cell lymphoma 2 (Bcl-2) family members enhanced the survival of the cells by inhibiting apoptosis. 36 A previous study demonstrated that loss of apoptotic signaling significantly hinders the response to targeted therapies 
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Future Direction
It is likely that optimal blockage of the MAPK pathway with dual or triple drug can lead to significant clinical benefit. There are initial results from the studies suggesting that the combination with anti-EGFR antibody and BRAF inhibitor with MEK inhibitor, PI3K inhibitor, BCL2 inhibitor, or irinotecan might be more effective than the 2 drugs. 30, 32, 33, 38 In addition, ERK inhibitor showed efficacy in reversing resistance in vitro 39 and is also in the early phase of a clinical trial.
Combination treatment strategies in BRAF mutant CRC are shown in Figure 1 , actionable drugs in proliferative pathway in Figure 2 , and ongoing studies that combine multiple potential drugs for BRAF mutant mCRC in Table 1 .
SUMMARY
BRAF mutated CRC is an aggressive subpopulation of mCRC. Despite recent advances in the knowledge at the molecular level of CRC, the prognosis in this group remains poor. Unlike BRAF mutated melanoma, BRAF inhibitor monotherapy has been reported ineffective in mCRC. Mitogen-activated protein kinase reactivation is a key mechanism of acquired resistance. The strategies that sustain inhibition of MAPK signaling pathway could control tumor proliferation and lead to an increase in survival. Therefore, treatments with BRAF-directed combination therapies may meaningfully change the outcome in BRAF mutated CRC patients. 
